Summarized by Masters of Longevity from PR Newswire.
An article previewing a biotech news story about regulatory progress and early clinical development of an in vivo CAR‑T therapy for autoimmune hemolytic anemia, inviting readers to learn about the therapy’s development pathway and clinical interest.
Key Takeaways
- The FDA granted Orphan Drug Designation to GT801 for treating autoimmune hemolytic anemia.
- Preliminary clinical data showed two AIHA patients achieved complete responses after GT801 treatment.
- GT801 is an in vivo CAR-T using mRNA delivered by T-cell-targeted lipid nanoparticles to deplete CD19-positive B cells.
